In vivo evaluation of limonene-based transdermal therapeutic system of nicorandil in healthy human volunteers

Skin Pharmacology and Physiology

Volumn 18, Issue 6, 2005, Pages 263-272

  Krishnaiah, Y S R ^a   Chandrasekhar, D V ^b   Rama, B ^b   Jayaram, B ^b   Satyanarayana, V ^c   Al Saidan, S M ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b ANDHRA UNIVERSITY   (India)

^c Sipra Labs Pvt Ltd   (India)

Author keywords

Human volunteers; Limonene; Transdermal therapeutic system

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; LIMONENE; NICORANDIL;

ADULT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; GEL; HUMAN; MALE; MEMBRANE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; SKIN; STEADY STATE; TABLET;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; ANIMALS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYCLOHEXENES; DRUG DELIVERY SYSTEMS; FOREARM; GELS; HUMANS; MALE; METHYLCELLULOSE; NICORANDIL; PERMEABILITY; RATS; SKIN; SKIN ABSORPTION; SOLVENTS; TERPENES; TISSUE ADHESIVES; VASODILATOR AGENTS;

EID: 27344450859     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087607     Document Type: Article

References (27)

1. Frampton J, Buckley MM, Fitton A: Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs 2002;44:625-655.
2. Kerins DM, Robertson RM, Robertson D: Drugs used for the treatment of myocardial ischemia; in Hardman JG, Limbird LE (eds): Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, McGraw Hill Medical Publishing Division, 2001, p 864.
3. Frydman A: Pharmacokinetic profile of nicorandil in humans: An overview. J Cardiovasc Pharmacol 1992;20(suppl 3):S34-S44.
4. Prausnitz MR, Mitragotri S, Langer R: Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004;3:115-124.
5. Elias PM: The stratum corneum revisited. J Dermatol 1996;23:756-758.
6. Williams AC, Barry BW: Penetration enhancers. Adv Drug Deliv Rev 2004;56:603-618.
7. El-Kattan AF, Asbill CS, Kim N, Michniak BB: The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities. Int J Pharm 2001;215:229-240.
8. Sato K, Sugibayashi K, Morimoto Y: Species differences in percutaneous absorption of nicorandil. J Pharm Sci 1991;80:104-107.
9. Sato K, Sugibayashi K, Morimoto Y, Omiya H, Enomoto N: Prediction of the in-vitro human skin permeability of nicorandil from animal data. J Pharm Pharmacol 1989;41:379-383.
10. Al-Saidan SM, Krishnaiah YSR, Chandrasekhar DV, Lalla JK, Rama B, Jayaram B, Bhaskar P: Formulation of an HPMC gel drug reservoir system with ethanol-water as a solvent system and limonene as a penetration enhancer for enhancing in vitro transdermal delivery of nicorandil. Skin Pharmacol Physiol 2004;17:310-320.
11. Diez I, Colom H, Moreno J, Obach R, Peraire C, Domenech J: A comparative in vitro study of transdermal absorption of a series of calcium channel antagonists. J Pharm Sci 1991;80:931-934.
12. Krishnaiah YSR, Satyanarayana V, Bhaskar P: Influence of menthol and pressure sensitive adhesives on the in vivo performance of membrane-moderated transdermal therapeutic system of nicardipine hydrochloride in human volunteers. Eur J Pharm Biopharm 2003;55:329-337.
13. Wester RC, Maibach HI: Regional variation in percutaneous absorption; in Bronaugh RL, Maibach HI (eds): Percutaneous Absorption; Drugs - Cosmetics - Mechanisms - Methodology, ed 3. New York, Dekker, 1999, pp 107-116.
14. Wester RC, Maibach HI: Regional variations in percutaneous absorption; in Bronaugh RL, Maibach HI (eds): Percutaneous Absorption, ed 2. New York, Dekker, 1989, pp 111-120.
15. Berardesca E, Maibach HI: Racial differences in pharmacodynamic response to nicotinates in vivo in human skin: Black and white. Acta Derm Venereol 1990;70:63-66.
16. Lotte C, Wester RC, Rougier A, Maibach HI: Racial differences in the in vivo percutaneous absorption of some organic compounds: A comparison between black, Caucasian and Asian subjects. Arch Dermatol Res 1993;284:456-459.
17. Berardesca E, de Rigal J, Leveque JL, Maibach HI: In vivo biophysical characterization of skin physiological differences in races. Dermatologica 1991;182:89-93.
18. Yosipovitch G, Sackett-Lundeen L, Goon A, Yiong Huak C, Leok Goh C, Haus E: Circadian and ultradian (12 h) variations of skin blood flow and barrier function in non-irritated and irritated skin-effect of topical corticosteroids. J Invest Dermatol 2004;122:824-829.
19. Yosipovitch G, Xiong GL, Haus E, Sackett-Lundeen L, Ashkenazi I, Maibach HI: Time dependent variations of the skin barrier function in humans: Transepidermal water loss, stratum corneum hydration, skin surface pH and skin temperature. J Invest Dermatol 1998;110:20-23.
20. Denda M, Tsuchiya T: Barrier recovery rate varies time dependently in human skin. Br J Dermatol 2000;142:881-884.
21. Le Fur I, Reinberg A, Lopez S, Morizot F, Mechkouri M, Tschachler E: Analysis of circadian and ultradian rhythms of skin surface properties of face and forearm of healthy women. J Invest Dermatol 2001;117:718-724.
22. Smolander J, Harma M, Lindqvist A, Kolari P, Laitinen LA: Circadian variation in peripheral blood flow in relation to core temperature at rest. Eur J Appl Physiol 1993;67:192-196.
23. Caspary L, Nordbruch S, Lange R, Creutzig A: Circadian variation of skin perfusion in arterial occlusive disease. Vasa 1997;26:194-198.
24. Bruguerolle B, Giaufre E, Prat M: Temporal variations in transcutaneous passage of drugs: The example of lidocaine in children and in rats. Chronobiol Int 1991;8:277-282.
25. Reinberg AE, Soudant E, Koulbanis C, Bazin R, Nicolai A, Mechkouri M, Touitou Y: Circadian dosing time dependency in the forearm skin penetration of methyl and hexyl nicotinate. Life Sci 1995;57:1507-1513.
26. Pershing LK, Corlett JL, Lambert LD, Ponclet CE: Circadian rhythm of topical 0.05% beta-methasone diproprionate in human skin in vivo. J Invest Dermatol 1994;102:734-739.
27. Meikle AW, Arver S, Dobs AS, Sanders SW, Mazer NA: Androderm: A permeation-enhanced non-scrotal testosterone trandermal system for the treatment of male hypogonadism; in Bhasin S, Gabelnick HL, Spieler JM, Swerdloff RS, Wang C (eds): Pharmacology, Biology, and Clinical Applications of Androgens. New York, Wiley-Liss, 1996, pp 449-457.